fda compounding semaglutide news october 2025 U.S. | The FDA has approved a new higher dose (7.2 mg) of Wegovy ( semaglutide) injection, Wegovy HD, for weight loss and long-term weight Compounded GLP-1 Statistics 2026 |

It is critical to reiterate that long-term human safety data is non-existent

Initiation of renal replacement therapy tended to decrease, but did not reach to statistical significance (HR 0.84, 95% CI 0.631.12)

Aetnas typical PA requirements for Wegovy and Zepbound include: Documented BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea) Evidence of participation in a structured weight management program (diet, exercise, behavioral counseling) for a minimum period often 3 to 6 months Documentation that other weight loss interventions have been attempted Prescriber must be a physician, NP, or PA with appropriate prescribing authority Prior authorization is not a denial it is a documentation requirement

Due to the retrospective nature of the study, the Ethics Committee of Omi Medical Center waived the need of obtaining informed consent

Texas produced 25,600